PHVS Pharvaris N.V.
Price Chart
Executive Summary
Five Pharvaris insiders, including the CEO and CCO, sold a total of ~$1.08M in open-market sales over a 7-day window, following a $107.5M equity offering that closed 14 days prior. The sales represent ~0.05% of the $2.1B market cap — a trivial amount — and are likely liquidity-driven after the offering's lock-up expiration rather than a bearish signal on the pipeline.
Key Financial Metrics
Actionable Insight
The insider sales are routine post-offering liquidity events — no bearish signal. Monitor the upcoming Phase 3 data readout for deucrictibant (expected H2 2026) as the primary catalyst. The $107.5M raise provides runway into H1 2028, reducing near-term financing risk.
Key Facts
- Five insiders sold a combined ~36,300 shares for ~$1.08M in open-market transactions (May 13-20, 2026).
- CEO Berndt Modig sold 2,292 shares for ~$67K; CCO Wim Souverijns sold 10,000 shares for ~$299K.
- Total sales equal ~0.05% of Pharvaris' $2.1B market cap — well below the 0.1% materiality threshold.
- The cluster follows a $107.5M underwritten public offering (424B5, May 8, 2026) that extended cash runway into H1 2028.
- Director Elisabeth Bjork also exercised 10,000 options at $8.05/share ($80,500 cost) and sold the shares for $293K — a net cash-out of ~$213K.
- Historical calibration shows cluster sells at this company have no predictive edge (score-6 observedP=29%, avg net alpha -0.96%).
Financial Impact
Total insider sales of ~$1.08M, or 0.05% of market cap — immaterial relative to company size.
Risk Factors
- Phase 3 clinical trial failure for deucrictibant in HAE would be a material negative catalyst.
- Further insider selling at higher volumes (>0.5% of market cap) could signal loss of confidence.
- Cash burn rate may accelerate if US commercialization costs ramp faster than expected.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1779476076663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
16d ago
|
Press Release
| $30.16 $31.09 | ▲ +3.08% | ▲ +5.61% | $30.72 (+1.86%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $29.47 $30.14 | ▲ +2.27% | ▲ +1.80% | $30.72 (+4.24%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $29.47 $30.14 | ▼ −2.27% | ▼ −1.80% | $30.72 (−4.24%) |
|
May 22, 2026
23d ago
|
Insider Cluster
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.63% | $30.72 (+3.50%) |
|
May 21, 2026
24d ago
|
144
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.61% | $30.72 (+3.50%) |
|
May 20, 2026
25d ago
|
Insider Cluster
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $30.72 (+0.59%) |
|
May 20, 2026
25d ago
|
144
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $30.72 (+0.59%) |
|
May 19, 2026
26d ago
|
Insider Cluster
| $29.45 $29.86 | ▲ +1.39% | ▼ −0.41% | $30.72 (+4.31%) |
|
May 12, 2026
4w ago
|
Press Release
| $32.94 $28.95 | ▼ −12.11% | ▼ −10.95% | $30.72 (−6.74%) |
|
May 11, 2026
4w ago
|
6-K
| $31.25 $28.81 | ▼ −7.81% | ▼ −7.89% | $30.72 (−1.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access